US 12,144,839 B2
Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 AB-based treatment
Laurence Zitvogel, Paris (FR); Bertrand Routy, Paris (FR); and Emmanuelle Le Chatelier, Magny les Hameaux (FR)
Assigned to INSTITUT GUSTAVE ROUSSY, Villejuif (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, Paris (FR); UNIVERSITE PARIS-SACLAY, Gif-sur-Yvette (FR); and Institut national de recherche pour l'agriculture, l'alimentation et l'environnement, Paris (FR)
Filed by INSTITUT GUSTAVE ROUSSY, Villejuif (FR); INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE—INSERM, Paris (FR); UNIVERSITE PARIS-SACLAY, Gif-sur-Yvette (FR); and Institut national de recherche pour l'agriculture, l'alimentation et l'environnement, Paris (FR)
Filed on Apr. 13, 2023, as Appl. No. 18/300,049.
Application 18/300,049 is a continuation of application No. 16/472,778, granted, now 11,684,640, previously published as PCT/EP2017/084552, filed on Dec. 22, 2017.
Claims priority of application No. 16306779 (EP), filed on Dec. 22, 2016; and application No. 17305206 (EP), filed on Feb. 24, 2017.
Prior Publication US 2023/0263843 A1, Aug. 24, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/744 (2015.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C12Q 1/6886 (2018.01); C12Q 1/689 (2018.01)
CPC A61K 35/744 (2013.01) [A61K 39/39558 (2013.01); C12Q 1/6886 (2013.01); C12Q 1/689 (2013.01); A61K 2039/55594 (2013.01); A61K 2039/585 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01)] 4 Claims
 
1. A method of treating a cancer amenable to Nivolumab or Pembrolizumab anti-PD1 antibody therapy in a patient, comprising administering to the gut of the patient a fecal microbial composition comprising Akkermansia muciniphila bacteria, in combination with Nivolumab or Pembrolizumab anti-PD1 therapy.